Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Laurie Iciek"'
Autor:
Julie Douthwaite, Jacques Moisan, Cyril Privezentzev, Blagoje Soskic, Shereen Sabbah, Suzanne Cohen, Andie Collinson, Elizabeth England, Catherine Huntington, Ben Kemp, Li Zhuang, Suzanne Hudak, D. Gareth Rees, Debbie Goldberg, Chris Barton, Linda Chang, Inna Vainshtein, Meina Liang, Laurie Iciek, Philip Ambery, Mark Peakman, Tristan J. Vaughan, Tim I. M. Tree, David M. Sansom, Michael A. Bowen, Ralph R. Minter, Lutz Jermutus
Publikováno v:
Journal of immunology (Baltimore, Md. : 1950). 199(5)
Autor:
Bettina Donato-Weinstein, Kamille O'Connor, Theresa LaVallee, Zhenling Yao, Feng Jin, Inna Vainshtein, Laurie Iciek, Amy Schneider, Meina Liang, Lorin Roskos, Mikhail Zusmanovich, Rozanne Lee, Bing Wang
Publikováno v:
Journal of Pharmaceutical Sciences. 102:250-261
Moxetumomab pasudotox is an immunotoxin currently being investigated in patients for the treatment of CD22-expressing B-cell malignancies. A single-cycle pharmacokinetic (PK)-pharmacodynamic (PD) study was conducted in cynomolgus monkeys for PK compa
Autor:
Greg Erexson, Kim Li, Susanne Glowienke, Lee M. Nagao, Andrew Teasdale, Uma S. Bruen, Thomas H. Broschard, Douglas J. Ball, Cheryl L. M. Stults, Laurie Iciek, Elizabeth A. Martin
Publikováno v:
Regulatory toxicology and pharmacology : RTP. 81
Leachables from pharmaceutical container closure systems can present potential safety risks to patients. Extractables studies may be performed as a risk mitigation activity to identify potential leachables for dosage forms with a high degree of conce
Autor:
Tristan J. Vaughan, Linda Chang, Laurie Iciek, Timothy Tree, Philip Ambery, Elizabeth England, Inna Vainshtein, Debbie Goldberg, Catherine Huntington, Meina Liang, Suzanne Hudak, Suzanne Cohen, Chris Barton, Mark Peakman, Julie A. Douthwaite, Ben Kemp, Blagoje Soskic, Jacques Moisan, Li Zhuang, Ralph Minter, D. Gareth Rees, Andie Collinson, Shereen Sabbah, Michael A. Bowen, Lutz Jermutus, David M. Sansom, Cyril Privezentzev
Publikováno v:
Journal of immunology (Baltimore, Md. : 1950). 198(1)
Affinity- and stability-engineered variants of CTLA4-Ig fusion molecules with enhanced pharmacokinetic profiles could yield improved therapies with the potential of higher efficacy and greater convenience to patients. In this study, to our knowledge,
Publikováno v:
Expert opinion on drug discovery. 5(1)
The prediction of human toxicity by employing animal models for nonclinical safety evaluation of pharmaceuticals poses numerous challenges. Each type, biologics, vaccines and small molecules, has unique features, which may impact the ability to effec
Autor:
Laurie Iciek
Publikováno v:
Immunotoxicology Strategies for Pharmaceutical Safety Assessment
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0c0d30c79434a5a5cfe0f737a8692174
https://doi.org/10.1002/9780470386385.ch9
https://doi.org/10.1002/9780470386385.ch9
Autor:
Yuling Wu, Robert E. Hollingsworth, Ching Ching Leow, Brett Hall, Jenny Liu, Laurie Iciek, Erin Sult, Qihui Huang, Ronald Herbst, Nicholas Holoweckyj, Kris Sachsenmeier, Nicholas M. Durham
Publikováno v:
Cancer Research. 75:1538-1538
CD73 is an ectonucleotidase that converts extracellular AMP to Adenosine. Within the tumor microenvironment, adenosine produced by CD73 is believed to have an immunosuppressive effect upon anti-tumor immunity. CD73 is found on lymphoid and myeloid ce
Autor:
Chris Tse, Joy Bauch, Kennan C. Marsh, Steven W. Elmore, Richard E. Nelson, Sherry J. Morgan, Glenn A. Reinhart, Saul H. Rosenberg, Ryan M. Fryer, Morey L. Smith, Laurie Iciek
Publikováno v:
Blood. 108:4236-4236
We recently disclosed the discovery of ABT-737, a potent antagonist of antiapoptotic Bcl-2 family proteins that induced tumor regression in murine xenograft models. ABT-263 is a related, orally bioavailable Bcl-2 family protein inhibitor that is curr